Inovio Piotroski F Score

INO
 Stock
  

USD 1.98  0.06  3.13%   

This module uses fundamental data of Inovio Pharmaceuticals to approximate its Piotroski F score. Inovio Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Inovio Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Inovio Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please see Inovio Pharmaceuticals Altman Z Score, Inovio Pharmaceuticals Correlation, Inovio Pharmaceuticals Valuation, as well as analyze Inovio Pharmaceuticals Alpha and Beta and Inovio Pharmaceuticals Hype Analysis.
  
Total Debt is expected to rise to about 41.5 M this year. Debt Current is expected to rise to about 2.7 M this year. Inovio Pharmaceuticals Revenue to Assets are quite stable at the moment as compared to the past year. The company's current value of Revenue to Assets is estimated at 0.003673. Asset Turnover is expected to rise to 0.003517 this year, although the value of Return on Investment will most likely fall to (72.67) .
At this time, it appears that Inovio Pharmaceuticals' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
1
Current Return On AssetsNegativeFocus
2
Change in Return on AssetsDecreasedFocus
3
Cash Flow Return on AssetsNegativeFocus
4
Current Quality of Earnings (accrual)ImprovingFocus
5
Asset Turnover GrowthIncreaseFocus
6
Current Ratio ChangeDecreaseFocus
7
Long Term Debt Over Assets ChangeHigher LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginNo ChangeFocus

Inovio Pharmaceuticals Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Inovio Pharmaceuticals is to make sure Inovio is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Inovio Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Inovio Pharmaceuticals' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted225.3 M208.8 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares225.3 M208.8 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities70.9 M65.7 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities103.9 M96.3 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Total Debt41.5 M33 M
Significantly Up
Decreasing
Slightly volatile
Asset Turnover0.00350.0034
Fairly Up
Decreasing
Slightly volatile
Current Assets483.8 M448.4 M
Significantly Up
Increasing
Slightly volatile
Total Assets535.1 M495.9 M
Significantly Up
Increasing
Slightly volatile

Inovio Pharmaceuticals F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Inovio Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Inovio Pharmaceuticals in a much-optimized way.

About Inovio Pharmaceuticals Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Weighted Average Shares

225.32 Million

Inovio Pharmaceuticals Weighted Average Shares is quite stable at the moment as compared to the past year. The company's current value of Weighted Average Shares is estimated at 225.32 Million

Inovio Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Inovio Pharmaceuticals from analyzing Inovio Pharmaceuticals' financial statements. These drivers represent accounts that assess Inovio Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inovio Pharmaceuticals' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(315.02 K)(336.69 K)(615.25 K)(633.42 K)(957.91 K)(1.03 M)
Revenue Per Employee150.79 K105.84 K21.2 K28.21 K5.6 K5.75 K
Average Assets175.77 M148.6 M162.93 M439.92 M569.6 M614.57 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(86.3 M)(90.77 M)(110.8 M)(153.95 M)(301.13 M)(309.06 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(84.71 M)(89.8 M)(106.15 M)(153.08 M)(296.99 M)(304.81 M)
Earnings before Tax(88.21 M)(94.8 M)(119.62 M)(166.41 M)(303.66 M)(311.65 M)
Average Equity133.42 M103.74 M42.16 M288.91 M485.85 M524.21 M
Enterprise Value349.64 M361.99 M407.22 M1.4 B1.02 B827.4 M
Free Cash Flow(73.5 M)(75.64 M)(98.84 M)(179.5 M)(216.94 M)(222.65 M)
Invested Capital111.52 M56.85 M175.07 M272.73 M378.94 M408.86 M
Invested Capital Average101.15 M73.22 M193.72 M265.22 M466.73 M503.57 M
Market Capitalization372.92 M381.39 M330.03 M1.5 B1.05 B863.97 M
Tangible Asset Value170.72 M115.84 M129.74 M526.11 M482.8 M520.92 M
Working Capital102.96 M52.52 M62.21 M429.46 M382.7 M412.92 M

About Inovio Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus , cancer, and infectious diseases. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. Inovio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 317 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inovio Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now

   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inovio Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Inovio Pharmaceuticals Altman Z Score, Inovio Pharmaceuticals Correlation, Inovio Pharmaceuticals Valuation, as well as analyze Inovio Pharmaceuticals Alpha and Beta and Inovio Pharmaceuticals Hype Analysis. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for analysis

When running Inovio Pharmaceuticals price analysis, check to measure Inovio Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inovio Pharmaceuticals is operating at the current time. Most of Inovio Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Inovio Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inovio Pharmaceuticals' price. Additionally, you may evaluate how the addition of Inovio Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is Inovio Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
494 M
Quarterly Revenue Growth YOY
30.38
Return On Assets
(0.43) 
Return On Equity
(0.92) 
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Inovio Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.